It is important to contextualise this risk: obesity itself is an independent risk factor for pancreatitis, as are conditions commonly associated with excess weight such as gallstones, hypertriglyceridaemia, and type 2 diabetes
| Parameter | Orforglipron (oral pill) | Retatrutide (injectable peptide) | | --- | --- | --- | | Molecular class | Non-peptide small molecule | Peptide (amino acid chain) | | Receptor profile | GLP-1 (single target) | GIP + GLP-1 + glucagon (triple) | | Administration | Oral, tablet | Subcutaneous injection | | Interval | Once daily | Once weekly | | Half-life | Short (daily dosing) | approx
Ongoing monitoring and open communication between patients and providers are essential for navigating these complexities, ensuring that the therapeutic advantages of semaglutide are realized while minimizing any potential impacts on hormonal health and well-being
Weight loss can feel like an uphill battle: balancing a busy life, managing stress, and finding time for health often makes it even harder
It remains, for now, a wellness hypothesis rather than convincingly evidence-based clinical protocol
Glucometabolic consequences of acute and prolonged inhibition of fatty acid oxidation
